Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor

Key facts

Sponsor

Staidson (Beijing) Biopharmaceuticals Co., Ltd

Principal Investigator

Lei Zhang, Ph.D

Hospital of Hematology, Chinese Academy of Medical Sciences

Intervention

STSP-0601 for Injection(drug)

Enrollment

25 enrolled

Eligibility

18-70 years · All sexes

Timeline

2024 – 2024

Study locations (20)

• Anhui Provincial Hospital, Hefei, Anhui, China
• The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
• Fujian Medical University Affiliated Union Medical College Hospital, Fuzhou, Fujian, China
• Lanzhou University First Hospital, Lanzhou, Gansu, China
• Southern Medical University Southern Hospital, Guangzhou, Guangdong, China
• Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
• Guizhou Medical University Affiliated Hospital, Guiyang, Guizhou, China
• Harbin First Hospital Hematology Tumor Research Center, Harbin, Heilongjiang, China
• Henan Cancer Hospital, Zhengzhou, Henan, China
• Xiangya Hospital of Central South University, Changsha, Hunan, China
• Nanjing University School of Medicine Affiliated Gulou Hospital, Nanjing, Jiangsu, China
• The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
• The first hospital of Jilin University, Changchun, Jilin, China
• Shengjing Hospital Affiliated to China Medical University, Shenyang, Liaoning, China
• Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
• +5 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE4NCT07406139
  PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）
  Institute of Hematology & Blood Diseases Hospital, China
• RECRUITINGPHASE3NCT04563520
  SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
  Emory University
• RECRUITINGNCT07101926
  Monitoring of Anti-TFPI in Hemophilia
  Hospices Civils de Lyon
• RECRUITINGPHASE4NCT06941870
  Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
  Sanofi
• RECRUITINGNCT07314983
  Long-term Anticoagulation in a Patient With Severe Hemophilia A
  University Hospital, Strasbourg, France
• RECRUITINGPHASE4NCT06940830
  Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa
  Swedish Orphan Biovitrum
• RECRUITINGPHASE1NCT06703606
  A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
  Pfizer
• RECRUITINGPHASE3NCT06833983
  To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
  Gritgen Therapeutics Co., Ltd.

See all trials for Hemophilia →